Perspective Therapeutics CATX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $21.37M+49.1% | $32.92M+156% | $20.34M+69.1% | $16.62M+79.2% | $14.33M+92.3% | ||
| $6.99M-10.9% | $6.95M-15.7% | $7.73M+10.8% | $7.71M+39.8% | $7.84M+33.4% | ||
| —— | $0-100% | $0— | $0— | $0— | ||
| $28.36M+27.9% | $39.88M-11.8% | $28.07M+47.7% | $24.33M+64.5% | $22.17M+66.3% | ||
| $28.36M+27.9% | $39.88M-11.8% | $28.07M+47.7% | $24.33M+64.5% | $22.17M+66.3% | ||
| -$28.28M-29.5% | -$39.83M+11.5% | -$27.86M-49.5% | -$24.04M-68.5% | -$21.83M-67.9% | ||
| $2.2M-7.8% | $1.61M-39.0% | $1.96M-45.4% | $2.16M-29.8% | $2.38M+96.9% | ||
| $2.09M-42.8% | $1.55M-43.0% | $1.89M-46.1% | $2.04M-33.1% | $3.66M+210% | ||
| —— | -$38.28M+9.4% | -$25.97M-71.7% | -$22M-96.2% | -$18.18M-53.7% | ||
| -$26.19M-44.1% | -$37.49M+6.7% | -$25.97M-71.7% | -$21.49M-83.6% | -$18.18M-48.0% | ||
| —— | $0— | $0— | $514K+205% | $0+100% | ||
| -$0.250.0% | -$0.51+16.4% | -$0.35-66.7% | -$0.29-61.1% | -$0.250.0% | ||
| -$0.250.0% | -$0.51+16.4% | -$0.35-66.7% | -$0.29-61.1% | -$0.250.0% | ||
| 103.6M+43.2% | 73.8M+14.6% | 74.3M+5.2% | 74.2M+11.4% | 72.4M+46.1% | ||
| 103.6M+43.2% | 73.8M+14.6% | 74.3M+5.2% | 74.2M+11.4% | 72.4M+46.1% | ||
| $105K-18.0% | $64K— | $65K-5.8% | $119K+417% | $128K+341% | ||
| -$26.53M-46.5% | -$37.49M+6.8% | -$25.86M-71.0% | -$21.5M-83.7% | -$18.11M-47.4% | ||
| —— | $0-100% | $0— | $0— | $0— | ||
| -$336K-580% | $0+100% | $111K— | -$16K— | $70K— | ||
| $0-100% | $0— | $0— | $0— | $1.4M— | ||
| $76K-77.8% | $43K-81.6% | $209K-43.4% | $290K-44.9% | $342K+5.2% | ||
| -$28.28M-29.5% | -$39.83M+11.5% | -$27.86M-49.5% | -$24.04M-68.5% | -$21.83M-67.9% | ||
| -$27.16M-28.7% | -$38.82M+12.3% | -$27.09M-50.8% | -$23.31M-70.2% | -$21.1M-66.8% | ||
| -$27.16M-28.7% | -$38.82M+12.3% | -$27.09M-50.8% | -$23.31M-70.2% | -$21.1M-66.8% | ||
| -$28.28M-29.5% | -$39.83M+11.5% | -$27.86M-49.5% | -$24.04M-68.5% | -$21.83M-67.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Perspective Therapeutics's revenue?
- Perspective Therapeutics (CATX) generated $10.0M in revenue over the trailing twelve months, up 0.5% year over year.
- Is Perspective Therapeutics profitable?
- Perspective Therapeutics is not currently profitable: it reported a net loss of $111.1M over the trailing twelve months, a -218.4% net margin.
- What are Perspective Therapeutics's profit margins?
- Gross margin is 33.1% and operating margin is -292.7%, with a -218.4% net margin.
- What is Perspective Therapeutics's earnings per share?
- Perspective Therapeutics's diluted EPS over the trailing twelve months is $-1.40.
- Where does Perspective Therapeutics's income statement data come from?
- Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
